

Performance of a Multiplier Score of the 99th Percentile of Troponin Level to Predict In-Hospital Events and one-year Mortality in Acute Coronary Syndrome

Rendimiento de un score multiplicador del percentilo 99 de troponina para predecir eventos intrahospitalarios y mortalidad a 1 año en el síndrome coronario agudo

SOL KERSTEN, ALAN R. SIGAL¹, MIRZA RIVERO^{MTSAC, 2}, JUAN F. FURMENTO³, DIEGO CONDE, MAYRA MEZA⁴, ANA SPACCAVENTO⁵, GASTÓN PROCOPIO⁶, JUAN PABLO COSTABEL^{MTSAC, 7}, REPRESENTING THE BOARD OF CARDIOVASCULAR EMERGENCIES AND CRITICAL CARDIOLOGY "DR. RAFAEL BULLRICH"

ABSTRACT

Background: In Argentina, high-sensitivity troponin is widely used to evaluate patients with chest pain. However, variability between assays (troponin I or T) and their different cut-off points and percentiles may hinder uniform interpretation.

Objective: This study assessed the performance of a multiplier score based on the 99th percentile of troponin level to predict in-hospital and one-year mortality, as well as ischemic and bleeding events in patients with acute coronary syndrome (ACS).

Methods: We used the ReSCAR registry, a prospective multicenter study that included patients with ACS. A total of 917 cases were analyzed: 291 with troponin I measurement and 626 with troponin T measurement. The multiplier score was calculated as the ratio of the troponin concentration to the 99th percentile of the corresponding assay. The area under the ROC curve (AUC ROC) of this score was evaluated regarding its ability to predict in-hospital ischemic and bleeding events, as well as in-hospital mortality and mortality at one-year follow-up.

Results: In-hospital mortality was 3.9%, while at one-year mortality was 7.2%. In-hospital ischemic events occurred in 8.2% of patients and bleeding events in 2.9%. The median score was 5.4 (IQR 1.2-48.2). The AUC ROC of the score to predict ischemic events was 0.64. No significant differences were observed when compared to the GRACE score (0.67). For bleeding events, the AUC ROC curve of the score was 0.63, comparable to that of the CRUSADE score (0.64). The discriminative ability of the score to predict in-hospital and one-year mortality was lower than that of the GRACE score (0.59 vs. 0.77 and 0.62 vs. 0.79, $p < 0.01$ for both).

Conclusion: The multiplier score based on the 99th percentile of troponin level is a simple and potentially useful tool for standardizing risk assessment in different centers which have diverse laboratories. Although its performance to predict in-hospital ischemic and bleeding events is comparable to that of the GRACE and CRUSADE scores, it showed lower accuracy to predict mortality.

Key words: Troponin – Score – Mortality – Acute Coronary Syndrome

RESUMEN

Introducción: En Argentina, la troponina de alta sensibilidad es ampliamente utilizada para evaluar pacientes con dolor torácico. Sin embargo, la variabilidad entre ensayos (troponina I o T) y sus diferentes puntos de corte y percentilos puede dificultar su interpretación uniforme.

Objetivo: Este estudio evaluó el desempeño de un *score* multiplicador basado en el percentilo 99 de troponina para predecir mortalidad intrahospitalaria y al año, así como eventos isquémicos y hemorrágicos en pacientes con síndrome coronario agudo (SCA).

Material y métodos: Se utilizó el registro ReSCAR, un estudio multicéntrico prospectivo que incluyó pacientes con SCA. Se analizaron 917 casos: 291 con troponina I y 626 con troponina T. El *score* multiplicador se calculó como la relación entre el dosaje de troponina y el percentilo 99 del ensayo correspondiente. Se evaluó el área bajo la curva ROC (ABC ROC) del *score* para predecir eventos isquémicos y hemorrágicos intrahospitalarios, al igual que para mortalidad intrahospitalaria y al año de seguimiento.

Resultados: La mortalidad hospitalaria fue 3,9% y al año 7,2%. Los eventos isquémicos intrahospitalarios ocurrieron en el 8,2% y los eventos hemorrágicos en 2,9% de los pacientes. La mediana del *score* fue 5,4 (rango intercuartílico 1,2-48,2). El ABC ROC del *score* para predecir eventos isquémicos fue 0,64, sin diferencias significativas con el *score* GRACE (0,67). Para eventos hemorrágicos, el *score* mostró un ABC ROC de 0,63, comparable a la del *score* CRUSADE (0,64). La capacidad discriminativa del *score* para mortalidad intrahospitalaria y al año fue menor que GRACE (0,59 vs. 0,77 y 0,62 vs. 0,79, $p < 0,01$ para ambos casos).

REV ARGENT CARDIOL 2025;93:25-30. <https://doi.org/10.7775/rac.v93.i1.20852>

SEE RELATED ARTICLE: REV ARGENT CARDIOL 2025;93:25-30. <https://doi.org/10.7775/rac.v93.i1.20860>

Received: 11/03/2024 – Accepted: 01/07/2025

Correspondence: Juan Pablo Costabel. Libertador 6302. Capital Federal. Argentina. E-mail: juanpablocostabel@gmail.com

This article won the Dr. Raúl Borraconi Award in the 50th Argentine Congress of Cardiology



<https://creativecommons.org/licenses/by-nc-sa/4.0/>

Conclusiones: El *score* multiplicador basado en el percentilo 99 de troponina es una herramienta simple y potencialmente útil para estandarizar la evaluación del riesgo en diferentes centros con distintos laboratorios. Aunque su desempeño es comparable al de GRACE y CRUSADE para eventos isquémicos y hemorrágicos intrahospitalarios, mostró menor precisión para predecir mortalidad.

Palabras claves: Troponina - *Score* - Mortalidad - Síndrome Coronario Agudo.

INTRODUCTION

Since its introduction around 2010, high-sensitivity troponin has become the biomarker of choice to diagnose acute myocardial infarction (AMI). (1-3) Both troponin T and I are integral components of myocardial cells, released from necrotic tissue, and exhibit high specificity for the diagnosis of AMI. (4) High-sensitivity assays offer improved sensitivity compared to other diagnostic tests, which increases their usefulness in emergency departments. (2, 3, 5)

Different studies have demonstrated that both troponin T and I provide high diagnostic accuracy for AMI, little variability in terms of symptom onset and multiple sampling, as well as high predictive value. (2, 3, 6-10) Today, most medical centers have access to these tests, but the distribution of assays and manufacturers is heterogeneous, and the centers use different cut-off points and percentiles. As a result, the collection of these values in multicenter studies has become a challenge that hinders the interpretation and correct analysis of data in acute coronary syndrome (ACS). Therefore, we propose a new system that uses the 99th percentile of the high-sensitivity troponin to standardize the different assays and assess their predictive ability.

METHODS

We performed a prespecified analysis of the patients included in ReSCAR, (11) a multicenter, prospective, observational registry performed in Argentina, which included patients with ACS from several centers of the country and collected data from history, ACS characteristics and treatment, as well as hospital events and patient status at one-year follow-up. ReSCAR included 984 patients with ST-elevation ACS or non-ST-elevation ACS from 15 centers in Argentina from January to August 2022.

Generation of a new score using the 99th percentile of troponin level

We transformed the high-sensitivity troponin value at admission, both troponin T assays and troponin I assays, into multiples of its 99th percentile, generating a new score. Only values at admission were included, regardless of whether they were the highest during hospital stay. For example, in a center, if a 99th percentile of troponin is 14 and the patient had a troponin of 28, his multiplier score (MS) is 2.

Comparison

To evaluate the effectiveness of the percentile, we compared its ability to predict ischemic and bleeding events with that of the GRACE (12) and CRUSADE (13) scores, analyzing the areas under the ROC curves. In addition, we evaluated the score ability to predict in-hospital and one-year follow-up

mortality, again comparing it with the GRACE score, and analyzing the ROC curve. Ischemic events were defined as AMI, stent thrombosis, stroke/transient ischemic attack (CVA/TIA) or post-infarction angina. Bleeding events were defined as those that were BARC 2 or greater. (14)

Data collection and inclusion criteria

As previously mentioned, we analyzed data from ReSCAR, an observational, cross-sectional, multicenter registry that included patients ≥ 18 years with ACS from several hospitals in Argentina, which had a coronary care unit, 24-hour hemodynamics service and ability to measure high-sensitivity troponin, from January to August 2022. Follow-up was carried out by telephone calls, and the information was complemented with data from medical records. Inclusion criteria were age ≥ 18 years, ST-elevation ACS or non-ST-elevation ACS, and a signed informed consent, whereas the only exclusion criterion was being lost to follow-up.

Data collected included history and ACS characteristics (type of ACS, Killip-Kimball scale, ECG findings), invasive or conservative strategy, time to coronary angiography (CA), treatment strategy, CA findings, ischemic, electrical and mechanical complications, requirement for mechanical ventilation and ventricular assistance, bleeding complications, in-hospital mortality and length of hospital stay.

Statistical analysis

Statistical analysis was performed with the IBM SPSS 25.0 software (for Mac iOS). Continuous variables were expressed as median and interquartile range (IQR) or mean and standard deviation, according to their distribution. Categorical variables were presented as frequencies and percentages. Normality analysis was performed using the Kolmogorov-Smirnov and Shapiro-Wilk tests.

The ROC curves were plotted using the sensitivity (true positive rate) and 1-specificity (false positive rate) of the 99th percentile of the high-sensitivity troponin for different endpoints: in-hospital ischemic events, in-hospital bleeding events, and in-hospital and one-year follow-up mortality. The area under the ROC curve (AUC ROC) was then calculated for each of these determinations, allowing the diagnostic threshold for the test to be calculated and compared with the traditional scores. Statistical significance was achieved when an alpha error $< 5\%$ was obtained.

Ethical considerations

All study participants signed an informed consent form prior to enrollment. This form explained the purpose of the study, the confidential nature of the information and the mechanisms used to protect the patient's identity. Participation was voluntary, and patients could refuse to take part in the study with no impact on their health care. Patients had the right to withdraw from the study at any time, according to their wishes.

Informed consent was submitted to the ethics committees of all medical centers for its approval, in accordance

with the regulations of the central Ethics Committee. This study was performed in compliance with the Argentina's Personal Data Protection Act No 25326. The identity of the patients and their personal data were anonymized. Only the investigators, the members of the teaching staff and the research ethics committees (if required) had access to data.

The study was conducted in accordance with the Argentine ethical standards: Act No. 3301, National Law on Clinical Research on Human Subjects, Declaration of Helsinki, (15) among others.

RESULTS

One hundred and eighty-two patients with positive serology total of 917 patients were included in the analysis, 291 with troponin I measurement and 626 with troponin T measurement, while 67 values could not be collected. Table 1 shows the baseline characteristics of the patients. The median age was 66 years, 25% of the patients were women, and the median left ventricular ejection fraction (LVEF) was 56%. Regarding medical history, 68% had a diagnosis of hypertension, 57% had dyslipidemia, 26% had diabetes, and 37.7% of patients were smokers. The median GRACE score was 131.2 (IQR 128.8-133.6), and the median CRUSADE score was 24.7 (IQR 23.7-24.7), while the median MS was 5.4 (IQR 1.2-48.2).

Regarding events, 38 patients (3.9%) died during hospitalization, and 71 (7.2%) died during the one-year follow-up. Eighty-one patients (8.2%) had an ischemic complication during initial hospitalization, 28 had an

AMI and 8 had a CVA/TIA, while 29 patients (2.9%) had a bleeding event (BARC ≥ 2). During follow-up, 55 patients (5.5%) had ischemic complications, including 14 (1.4%) who presented an AMI and 38 (3.9%) who required revascularization. Table 2 shows detailed ischemic and bleeding events.

When comparing our score with the GRACE score to predict ischemic events, the AUC ROC of our score was 0.64 (95% CI 0.57-0.71), while that of the GRACE score was 0.67 (95% CI 0.61-0.75), $p=0.512$. To evaluate the ability to predict bleeding events, we compared our score with the CRUSADE score and obtained an AUC ROC of 0.63 (95% CI 0.53-0.73) versus 0.64 (95% CI 0.57-0.78), $p=0.526$. Regarding mortality, when comparing the performance for in-hospital mortality, our score had an AUC ROC of 0.59 (95% CI 0.49-0.68), while that of the GRACE score was 0.77 (95% CI 0.68-0.86), $p=0.005$, demonstrating the superiority of the latter as a predictive factor. However, when analyzing the ability to predict mortality during follow-up, our score had a slightly better value, with an AUC ROC of 0.62 (95% CI 0.55-0.69), but still lower than the GRACE score, 0.79 (95% CI 0.73-0.85), $p=0.002$. Figure 1 shows the mentioned curves.

DISCUSSION

The heterogeneous distribution of the troponin assays has resulted in a variety of data for troponin levels in ACS. Therefore, unification and interpretation

Table 1. Baseline Characteristics (n=984)

Characteristic	Values
Age, years - median (IQR)	66 (56.5-74)
Female sex - n (%)	243 (24.7)
Hypertension - n (%)	671 (68.1)
Diabetes mellitus - n (%)	255 (25.9)
Dyslipidemia - n (%)	560 (56.9)
Smoking - n (%)	377 (37.7)
CKD - n (%)	69 (7)
Unstable angina - n (%)	219 (22.2)
STEMI - n (%)	236 (24)
NSTEMI - n (%)	385 (39.1)
Type II infarction - n (%)	40 (4.1)
Heart rate, bpm- median (IQR)	77 (70-88)
Systolic blood pressure, mmHg- median (IQR)	130 (120-150)
LVEF, %- median (IQR)	56 (45-60)
Troponin T - n (%)	626 (63.6)
Troponin I - n (%)	291 (29.6)
GRACE score - median (IQR)	131.2 (128.8-133.6)
CRUSADE score - median (IQR)	24.7 (23.7-24.7)
Multiplier score - median (IQR)	5.4 (1.2-48.2)

BPM: beats per minute; CKD: chronic kidney disease; IQR: interquartile range; LVEF: left ventricular ejection fraction; NSTEMI: non ST-segment elevation myocardial infarction; STEMI: ST-segment elevation myocardial infarction.

Event	Value
In-hospital AMI - n (%)	28 (2.7)
In-hospital stroke - n (%)	8 (0.8)
In-hospital bleeding (BARC ≥2) - n (%)	29 (2.9)
In-hospital mortality - n (%)	38 (3.9)
AMI at follow-up - n (%)	14 (1.4)
Stroke at follow-up - n (%)	3 (0.3)
Revascularization at follow-up - n (%)	38 (3.9)
HF at follow-up - n (%)	22 (2.2)
Mortality at follow-up - n (%)	33 (3.7)
Total AMI - n (%)	42 (4.1)
Total stroke - n (%)	11 (1.1)
Total mortality - n (%)	71 (7.2)

AMI: acute myocardial infarction; BARC: Bleeding Academic Research Consortium; HF: heart failure.

Table 2. Ischemic and bleeding events

of those results, as well as their use in multicenter studies is challenging. The use of the MS of the 99th percentile of troponin could harmonize the different assays and mitigate those differences. To assess its predictive ability, we compared it with conventional score systems for ischemic events, bleeding events, and mortality. We highlight four findings in our work.


First, for bleeding events, the AUC ROC was 0.63, demonstrating a moderate predictive ability for this endpoint, which was not statistically different from that of the CRUSADE score, 0.64. (13) Other studies have already demonstrated the predictive value of the troponin for bleeding events, such as the study by Mathews et al., which demonstrated an increasing risk based on the troponin level on admission. (16) Iser et al. showed an increased risk of gastrointestinal bleeding in patients with elevated troponin, (17) while Al-Mallah et al. observed an increased overall bleeding risk according to the peak troponin value in acute coronary syndromes. (18) Furthermore, in terms of predictive value, the ABC score to predict bleedings in patients with atrial fibrillation, including biomarkers such as the high-sensitivity troponin, was shown to be superior to that of the HAS-BLED and ORBIT scores. (19) These results could be attributed to the elevated troponin levels generally observed in patients with chronic kidney disease, diabetes or advanced age, among others, where the risk of bleeding is usually higher.

Second, the predictive ability of the MS for ischemic events was modest. The AUC ROC was 0.64, which does not differ significantly from the values from the GRACE score (AUC ROC 0.67), which is the usual predictive tool to calculate ischemic risk in ACS. The ability of the troponin to predict ischemic events has been previously documented in the study by Blankenberg et al., where the troponin I was a predictor of cardiovascular and overall disease and mortality, (20)

or in the study by Lindahl that showed similar results. (21,22)

Third, for in-hospital mortality, the MS had limited ability as a predictive factor. The AUC ROC was 0.59 compared with 0.77 of the GRACE score. Although the marker could indicate higher risks, as above mentioned, the GRACE score also includes crucial patient parameters, such as cardiac arrest on admission, the Killip-Kimball assessment, and the incorporation of the patient's hemodynamic status into the equation. (23) Regarding mortality at one-year follow-up, our test showed an improved area under the curve (0.62), although this value was lower than that of the GRACE score (0.79). The above cited Blankenberg study showed that although the troponin is a predictor of mortality, the addition of this biomarker to other risk scores did not significantly modify the area under their ROC curves. (20) The same was documented by Meune et al. in their study, where it was shown that the GRACE score remains useful for determining in-hospital and long-term mortality in patients with ACS in the era of the high-sensitivity troponin, and that its addition, or the addition of the B-type natriuretic peptide (BNP) value to the score did not increase its predictive value. (24) In contrast, the study by Ordoñez et al. showed that troponin T was superior to the GRACE and TIMI scores when predicting adverse events and in-hospital mortality. However, in that study, AUC ROC was 0.52 for the GRACE score, clearly lower than that obtained in our population and that published in the literature, and ST-elevation infarctions were excluded. (25)

Finally, our results highlight that the MS could be a useful tool for data standardization in multicenter settings and for risk assessment in ACS. However, its ability to predict mortality is inferior to that of the established scores, such as GRACE and CRUSADE.



MS: multiplier score

Fig. 1. ROC curves for hospital events and per year.

This underscores the need to use the troponin to complement, rather than to replace, more comprehensive predictive tools in clinical practice.

Limitations

The retrospective characteristics of the analysis generate biases inherent to the type of study. In addition, the number of events was relatively low, which may make the results unrepresentative. We understand that the wide interquartile range of the MS contrasts with the narrower ranges of the GRACE and CRUSADE scores, although we do not believe that this influences the results. Besides, although centers from all over the country participated, only those centers of medium and high complexity with 24-hour access to hemodynamics were included, so the applicability of the score to patients from centers of lower complexity may be lower.

CONCLUSION

The use of the MS of the 99th percentile of troponin level in ACS may be a useful tool for harmonizing the vast and variable amount of assays and data available today, which hinders the accurate interpretation of information. As a simple tool, this new score system could help to standardize information worldwide and encourage new multicenter studies. Its predictive value is not inferior to that of the conventional risk scores, such as GRACE and CRUSADE, for both in-hospital ischemic and bleeding events.

Conflicts of interest

None declared.

(See authors' conflict of interests forms on the web).

Financing

No funding was required for this study.

REFERENCES

1. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction. *Circulation* 2018;138:e618-e651. <https://doi.org/10.1161/CIR.0000000000000617>
2. Trivi M, Costabel JP, Spennatto M, Duronto E, Caccavo A, Mauro V, et al. Consenso Síndrome Coronario Agudos sin Elevación del Segmento ST-2019. Versión resumida. Sociedad Argentina de Cardiología. *Rev Argent Cardiol* 2020;88:1-13.
3. Tajer C, Charask A, Castillo Costa Y, Alln J, Antonietti L, Berrocal D, et al. Consenso de síndrome coronario agudo con elevación ST. Actualización focalizada. 2019. Sociedad Argentina de Cardiología. *Rev Argent Cardiol* 2020;88:1-18.
4. Kozinski M, Krintus M, Kubica J, Synniewska G. High-sensitivity cardiac troponin assays: from improved analytical performance to enhanced risk stratification. *Crit Rev Clin Lab Sci* 2017;54:143-72. <https://doi.org/10.1080/10408363.2017.1285268>
5. Espinosa AS, Hussain S, Al-Awar A, Jha S, Elmahdy A, Kalani M, et al. Differences between cardiac troponin I vs. T according to the duration of myocardial ischaemia. *Eur Heart J Acute Cardiovasc Care* 2023;12:355-63. <https://doi.org/10.1093/ehjacc/zuad017>
6. Haaf P, Reichlin T, Twerenbold R, Hoeller R, Rubini Gimenez M, Zellweger C, et al. Risk stratification in patients with acute chest pain using three high-sensitivity cardiac troponin assays. *Eur Heart J* 2014;35:365-75. <https://doi.org/10.1093/eurheartj/ehu218>
7. Wanamaker BL, Seth MM, Sukul D, Dixon SR, Bhatt DL, Maddner RD, et al. Relationship between troponin on presentation and in-hospital mortality in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. *J Am Heart Assoc* 2019;8(19, article e013551). <https://doi.org/10.1161/JAHA.119.013551>
8. Willeit P, Welsh P, Evans JDW, Tschiderer L, Boachie C, Wouter Jukema J, et al. High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants. *J Am Coll Cardiol*. 2017;70:558-68. <https://doi.org/10.1016/j.jacc.2017.05.062>
9. Correia LC, Sodré FL, Lima JC, Sabino M, Brito M, Garcia G, et al. Prognostic value of high-sensitivity troponin I versus troponin T in acute coronary syndromes. *Arq Bras Cardiol* 2012;98:406-12. <https://doi.org/10.1590/S0066-782X2012005000034>
10. Rubini Gimenez M, Twerenbold R, Reichlin T, Wildi K, Haaf P, Schaefer M, et al. Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction. *Eur Heart J* 2014;35:2303-11. <https://doi.org/10.1093/eurheartj/ehu188>
11. Rivero M, Feder J, Procopio G, Gingins M, Souto JM, Villareal R, et al. Registro de síndromes coronarios agudos en centros de alta complejidad de Argentina. ReSCAR 2022. *Rev Argent Cardiol* 2023;91:205-211. <https://doi.org/10.7775/rac.es.v91.i3.20631>
12. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP et al; Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. *Arch Intern Med* 2003;163:2345-53. <https://doi.org/10.1001/archinte.163.19.2345>
13. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. *Circulation* 2009;119:1873-82. <https://doi.org/10.1161/CIRCULATIONAHA.108.828541>
14. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation* 2011;123:2736-47. <https://doi.org/10.1161/CIRCULATIONAHA.110.009449>
15. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. *JAMA* 2013;310:2191-4. <https://doi.org/10.1001/jama.2013.281053>
16. Mathews L, Ishigami J, Ding N, Hoogeveen RC, Kucharska-Newton A, Ballantyne CM, et al. Cardiac Biomarkers and Subsequent Risk of Hospitalization With Bleeding in the Community: Atherosclerosis Risk in Communities Study. *J Am Heart Assoc* 2020;9:e013560. <https://doi.org/10.1161/JAHA.119.013560>
17. Iser DM, Thompson AJ, Sia KK, Yeomans ND, Chen RY. Prospective study of cardiac troponin I release in patients with upper gastrointestinal bleeding. *J Gastroenterol Hepatol* 2008;23:938-42. <https://doi.org/10.1111/j.1440-1746.2007.04940.x>
18. Al-Mallah M, Bazari RN, Jankowski M, Hudson MP. Predictors and outcomes associated with gastrointestinal bleeding in patients with acute coronary syndromes. *J Thromb Thrombolysis* 2007;23:51-5. <https://doi.org/10.1007/s11239-006-9005-8>
19. Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, et al; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. *Lancet* 2016;387:2302-11. [https://doi.org/10.1016/S0140-6736\(16\)00741-8](https://doi.org/10.1016/S0140-6736(16)00741-8)
20. Blankenberg S, Salomaa V, Makarova N, Ojeda F, Wild P, Lackner KJ, et al. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. *Eur Heart J* 2016;37:2428-37. <https://doi.org/10.1093/eurheartj/ehw172>
21. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of Myocardial Damage and Inflammation in Relation to Long-Term Mortality in Unstable Coronary Artery Disease. *N Engl J Med* 2000;343:1139-47. <https://doi.org/10.1056/NEJM200010193431602>
22. Lindahl B, Venge P, Wallentin L. Relation Between Troponin T and the Risk of Subsequent Cardiac Events in Unstable Coronary Artery Disease. *Circulation* 1996;93:1651-7. <https://doi.org/10.1161/01.CIR.93.9.1651>
23. Bradshaw PJ, Ko DT, Newman AM, Donovan LR, Tu JV. Validity of the GRACE (Global Registry of Acute Coronary Events) acute coronary syndrome prediction model for six month post-discharge death in an independent data set. *Heart* 2006;92:905-9. <https://doi.org/10.1136/hrt.2005.073122>
24. Meune C, Drexler B, Haaf P, Reichlin T, Reiter M, Meissner J, et al. The GRACE score's performance in predicting in-hospital and one-year outcome in the era of high-sensitivity cardiac troponin assays and B-type natriuretic peptide. *Heart* 2011;97:1479-83. <https://doi.org/10.1136/hrt.2010.220988>
25. Ordóñez S, Chillik I, Etchepare Á, Galizia Brito V, Burgos LM, Furmento JF, et al. High-sensitivity troponin t compared with GRACE and TIMI scores as predictors of in-hospital adverse events. *Revista CONAREC* 2017;33:295-99.